Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
53
0
0
36
Key Insights
Highlights
Success Rate
71% trial completion
Published Results
27 trials with published results (51%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
28.3%
15 terminated out of 53 trials
70.6%
-15.9% vs benchmark
6%
3 trials in Phase 3/4
75%
27 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (53)
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia
AML Therapy With Irradiated Allogeneic Cells
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia